Health care stocks fell late Friday afternoon with the NYSE Health Care Index declining 1.7% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.8%.
The iShares Biotechnology ETF (IBB) slumped 4.7%.
In corporate news, Eyenovia (EYEN) shares plunged 69%. A phase 3 study evaluating the drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia didn't meet the primary endpoint. Eyenovia also is considering options including a business combination, reverse merger or asset sales.
Bluebird Bio (BLUE) shares sank 11% after BofA Securities downgraded the company's stock to neutral from buy.
Halozyme Therapeutics (HALO) offered to buy German drugmaker Evotec (EVO) for 2 billion euros ($2.11 billion). Halozyme shares tumbled 15%, and Evotec jumped past 6%.
CERo Therapeutics (CERO) shares surged 52%. The US Food and Drug Administration cleared the company's investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。